Loss of efficacy and safety of the switch from infliximab original to infliximab biosimilar (CT-P13) in patients with inflammatory bowel disease

BACKGROUND: Infliximab original has changed the natural history of inflammatory bowel diseases (IBD) over the past two decades. However, the recent expiration of its patent has allowed the entry of the first Infliximab biosimilar into the European and Spanish markets. Currently switching drugs data i...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:World J Gastroenterol
Main Authors: Guerra Veloz, María Fernanda, Argüelles-Arias, Federico, Castro Laria, Luisa, Maldonado Pérez, Belén, Benítez Roldan, Antonio, Perea Amarillo, Raúl, Merino Bohórquez, Vicente, Calleja, Miguel Angel, Caunedo Álvarez, Ángel, Vilches Arenas, Ángel
פורמט: Artigo
שפה:Inglês
יצא לאור: Baishideng Publishing Group Inc 2018
נושאים:
Observational Study
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC6295832/
https://ncbi.nlm.nih.gov/pubmed/30581277
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3748/wjg.v24.i46.5288
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים